TY - JOUR
T1 - Autografting in chronic myeloid leukemia
AU - Carella, Angelo M.
AU - Beltrami, Germana
AU - Corsetti, Maria T.
PY - 2003/1
Y1 - 2003/1
N2 - Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis. Among 50 autografted patients who were treated with interferon alpha (IFN-α) and imatinib (for cytogenetic relapse after IFN-α), 41 are alive at a median of 51 months (range, 8 to 106 months). Twenty-eight (56%) patients maintain major cytogenetic remission after ASCT + IFN-α ± imatinib. Such results are probably better than those achieved by IFN-α alone and are similar to the best results obtained in younger patients after allografting with human leukocyte antigen (HLA)-identical sibling donors. The integration of imatinib, during the coming years, into an autografting procedure could represent important progress towards developing a cure for chronic myeloid leukemia (CML) patients who cannot undergo conventional allografting.
AB - Autografting (or autologous stem cell transplant [ASCT]) followed by "rescue" with Philadelphia chromosome (Ph)-negative hematopoietic progenitor cells (HPC) remains a good procedure to guarantee prolonged survival for patients mobilized and autografted soon after diagnosis. Among 50 autografted patients who were treated with interferon alpha (IFN-α) and imatinib (for cytogenetic relapse after IFN-α), 41 are alive at a median of 51 months (range, 8 to 106 months). Twenty-eight (56%) patients maintain major cytogenetic remission after ASCT + IFN-α ± imatinib. Such results are probably better than those achieved by IFN-α alone and are similar to the best results obtained in younger patients after allografting with human leukocyte antigen (HLA)-identical sibling donors. The integration of imatinib, during the coming years, into an autografting procedure could represent important progress towards developing a cure for chronic myeloid leukemia (CML) patients who cannot undergo conventional allografting.
UR - http://www.scopus.com/inward/record.url?scp=0037258489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037258489&partnerID=8YFLogxK
U2 - 10.1016/S0037-1963(03)70044-4
DO - 10.1016/S0037-1963(03)70044-4
M3 - Article
C2 - 12563613
AN - SCOPUS:0037258489
VL - 40
SP - 72
EP - 78
JO - Seminars in Hematology
JF - Seminars in Hematology
SN - 0037-1963
IS - 1
ER -